Global development of SSGJ707 accelerates, enhancing 3SBio's pipeline visibility

Overview

This report is Goldman Sachs' meeting takeaways on 3SBio following China Healthcare Corporate Day 2026, focusing on SSGJ707's global clinical development, the impact of anti-corruption policies on commercialization, sales team building across therapeutic areas, capital allocation, and valuation risks. The core conclusion is that SSGJ707 is accelerating toward global registrational development, enhancing pipeline visibility; near-term commercial execution is generally manageable, but policy disruptions still warrant tracking.

Core views

The report's core views include: first, under the Pfizer partnership, SSGJ707 has entered a broader stage of registrational studies, with multiple Phase 3 MRCTs and ADC combination strategies enhancing future commercialization and BD optionality; second, tighter anti-corruption policies have already caused a short-term slowdown in some sales and marketing activities, but demand for innovative drugs is more patient-driven and may be more resilient; third, the company plans to strengthen commercial capabilities in therapeutic areas such as oncology, immunology, and nephrology; fourth, the company is maintaining around US$3bn in cash and seeking a balance among shareholder returns, early-stage R&D, and strategic investments.

Analysis framework

The report adopts a meeting-takeaways-style fundamental analysis framework, combining management commentary, clinical pipeline progress, commercialization capabilities across therapeutic areas, capital allocation, and SOTP valuation to assess the investment implications for 3SBio. The valuation section values the existing product portfolio, SSGJ707, and the new drug pipeline separately, while incorporating key assumptions such as WACC, terminal growth rate, and FY26 PE.

Methodology notes

• Valuation methodsSOTP

  sum-of-the-parts valuation

  The target price of HK$29.43 is based on SOTP, including separate valuations for the existing product portfolio, SSGJ707, and the new drug pipeline.

• Valuation methodsDCF

  discounted cash flow

  SSGJ707 is valued at Rmb34.5bn and the new drug pipeline at Rmb13.3bn, both using a 9% WACC; the terminal growth rate is 0% for SSGJ707 and 1% for the new drug pipeline.

• Relative valuationPE

  price-to-earnings valuation

  The existing product portfolio is valued at Rmb13.2bn, based on FY26 PE of 10.4x.

• Factor analysisGS Factor Profile

  Goldman Sachs factor profile

  This framework compares a stock's growth, financial returns, valuation multiples, and composite score to provide investment context.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 3SBio Inc. (1530.HK)

  Company covered in the report

  Strengths

  Advancing global development of SSGJ707, high cash balance, rich oncology and immunology pipeline, and commercial foundations such as TPO and EPO.

  Weaknesses

  Commercial teams vary in maturity across some therapeutic areas, and anti-corruption policies may affect near-term sales and physician interactions.

  Comparison

  It is within Goldman Sachs' China biopharma coverage universe, alongside companies such as CSPC Pharma, Hansoh Pharma, Hengrui Medicine, and Zai Lab.

  Risks

  TPO pricing pressure, slower-than-expected ramp-up of new products, weak demand for Mandi, and SSGJ707 clinical development falling short of expectations.

• SSGJ707

  Core innovative drug pipeline asset

  Strengths

  Supported by the Pfizer partnership for global development, with multiple Phase 3 MRCTs advancing and room for expansion through ADC combination therapy.

  Weaknesses

  Execution risks remain in clinical development, registration, and technology transfer.

  Comparison

  It can form combination strategies with ADCs such as Padcev, and may also explore combinations with assets such as sigvotatug vedotin and fetrastobart vedotin.

  Risks

  Clinical data falling short of expectations, slow progress in combination therapy, or regulatory milestone timing or amounts coming in below expectations.

• TPO business

  Part of the existing commercial product portfolio

  Strengths

  Sales volume may remain broadly stable, new indications such as CLDT may contribute incremental growth, and increased clinical use of ADCs may also drive demand.

  Weaknesses

  ASP depends on NRDL negotiations for new indications, creating pricing pressure.

  Comparison

  It is one of the company's mature commercial foundations, forming a cash flow and growth combination with the innovative oncology pipeline.

  Risks

  Pricing pressure, flat or slightly declining sales volume, and uncertainty in negotiations for new indications.

Key data

• Report date2026-06-25Publication date of Goldman Sachs Equity Research.
• Conference dates2026-06-23 to 2026-06-26China Healthcare Corporate Day 2026.
• Target priceHK$29.4312-month target price, based on SOTP.
• Current priceHK$16.42Price shown in the company's related disclosure.
• Implied upsideapproximately 79.2%Estimated based on the target price of HK$29.43 and the current price of HK$16.42.
• SSGJ707 regulatory milestoneapproximately US$100-300mnRegulatory milestone payments that management expects may occur in 2026.
• Cash balanceapproximately US$3bnThe company maintains a large cash balance for shareholder returns, R&D, and strategic investments.
• Nephrology sales representativesapproximately 300-400The company is deeply cultivating the nephrology field based on its EPO business.
• SSGJ707 Phase 3 MRCTup to five ongoingSupported by Pfizer-led global development.

Impact & implications

If SSGJ707's global registrational studies progress smoothly, 3SBio's innovative pipeline value and international commercial potential will be further enhanced; the ADC combination therapy path may expand indication and combination opportunities. On the commercial side, anti-corruption policies may suppress near-term hospital promotion and prescription pacing, but the patient-demand-driven nature of innovative products should help cushion the impact. In capital allocation, the relatively high cash balance provides flexibility for dividends, buybacks, early-stage research investment, and external partnerships.

Risks

• TPO pricing pressure.
• Slower-than-expected sales ramp-up of new products.
• Weaker-than-expected demand for Mandi.
• SSGJ707 clinical development falling short of expectations.
• The impact of anti-corruption policies on sales, physician interactions, and prescription trends remains unclear.

What to watch

• Progress pace and key data readouts from multiple Phase 3 MRCTs of SSGJ707.
• Progress in global technology transfer, clinical supply responsibilities, and regulatory milestone payments under the Pfizer partnership.
• Whether combination therapy strategies with Padcev and other ADC assets will be implemented.
• The actual impact of anti-corruption policies on physician interactions, prescriptions, and sales pacing from June to August 2026.
• Expansion of commercial teams in oncology, immunology, and nephrology, and performance of new product launches.
• The impact of NRDL negotiations on ASP for new TPO indications.
• Changes in capital allocation among dividends, buybacks, early-stage R&D, and strategic investments.